Report Library
All Reports
Targeting HER3 in EGFR TKI-resistant EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
April 10, 2025
This analysis dives into the emerging HER3-targeted drugs and studies for EGFR-mutated NSCLC patients who have progressed on prior treatment with osimertinib/EGFR TKIs and platinum-based chemotherapies.
| Indications Covered: | Non-Small Cell Lung Cancer (NSCLC) |